{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:31:05Z","timestamp":1787164265218,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04172-3","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:34:14Z","timestamp":1762144454000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The immunophenotype of immune checkpoint-induced bullous pemphigoid: a cohort study"],"prefix":"10.1007","volume":"74","author":[{"given":"Nada","family":"Saffuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilanit","family":"Boyango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itay","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zenab","family":"Ali-Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Dawood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyad","family":"Khamaysi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Yogev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Avitan-Hersh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"issue":"1","key":"4172_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/ijd.17379","volume":"64","author":"D Li","year":"2025","unstructured":"Li D, Sun Y, Le J, Dian Y, Liu Y, Zeng F, Deng G, Lei S, Su J (2025) Predictors of survival in immunotherapy-based treatments in advanced melanoma: a meta-analysis. Int J Dermatol 64(1):15\u201323. https:\/\/doi.org\/10.1111\/ijd.17379","journal-title":"Int J Dermatol"},{"issue":"10304","key":"4172_CR2","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino MS, Larkin J, Long GV (2021) Immune checkpoint inhibitors in melanoma. Lancet 398(10304):1002\u20131014. https:\/\/doi.org\/10.1016\/S0140-6736(21)01206-X","journal-title":"Lancet"},{"issue":"36","key":"4172_CR3","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Ghosh M, Jaiyesimi I, Mammen JS, Naing A, Nastoupil LJ, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Funchain P, Bollin K (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39(36):4073\u20134126. https:\/\/doi.org\/10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"issue":"21","key":"4172_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215451","volume":"14","author":"W Shalata","year":"2022","unstructured":"Shalata W, Weissmann S, Itzhaki Gabay S, Sheva K, Abu Saleh O, Jama AA, Yakobson A, Rouvinov K (2022) A retrospective, single-institution experience of bullous pemphigoid as an adverse effect of immune checkpoint inhibitors. Cancers (Basel) 14(21):5451. https:\/\/doi.org\/10.3390\/cancers14215451","journal-title":"Cancers (Basel)"},{"key":"4172_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1095694","volume":"13","author":"J Wang","year":"2023","unstructured":"Wang J, Hu X, Jiang W, Zhou W, Tang M, Wu C, Liu W, Zuo X (2023) Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid. Front Oncol 13:1095694. https:\/\/doi.org\/10.3389\/fonc.2023.1095694","journal-title":"Front Oncol"},{"key":"4172_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.588582","volume":"11","author":"CD Sadik","year":"2021","unstructured":"Sadik CD, Langan EA, Gutzmer R, Fleischer MI, Loquai C, Reinhardt L, Meier F, G\u00f6ppner D, Herbst RA, Zillikens D, Terheyden P (2021) Retrospective analysis of checkpoint inhibitor therapy-associated cases of bullous pemphigoid from six German dermatology centers. Front Immunol 11:588582. https:\/\/doi.org\/10.3389\/fimmu.2020.588582","journal-title":"Front Immunol"},{"issue":"4","key":"4172_CR7","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.jaad.2019.08.045","volume":"82","author":"O Hasan Ali","year":"2020","unstructured":"Hasan Ali O, Bomze D, Ring SS, Berner F, F\u00e4ssler M, Diem S, Abdou MT, Hammers C, Emtenani S, Braun A, Cozzio A, Mani B, Jochum W, Schmidt E, Zillikens D, Sadik CD, Flatz L (2020) BP180-specific immunoglobulin G is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors. J Am Acad Dermatol 82(4):854\u2013861. https:\/\/doi.org\/10.1016\/j.jaad.2019.08.045","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"4172_CR8","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1111\/bjd.21836","volume":"187","author":"A Kawsar","year":"2022","unstructured":"Kawsar A, Edwards C, Patel P, Heywood RM, Gupta A, Mann J, Harland C, Heelan K, Larkin J, Lorigan P, Harwood CA, Matin RN, Fearfield L (2022) Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study. Br J Dermatol 187(6):981\u2013987. https:\/\/doi.org\/10.1111\/bjd.21836","journal-title":"Br J Dermatol"},{"issue":"6","key":"4172_CR9","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/ijd.13984","volume":"57","author":"AT Lopez","year":"2018","unstructured":"Lopez AT, Khanna T, Antonov N, Audrey-Bayan C, Geskin L (2018) A review of bullous pemphigoid associated with with PD-1 and PD-L1 inhibitors. Int J Dermatol 57(6):664\u2013669. https:\/\/doi.org\/10.1111\/ijd.13984","journal-title":"Int J Dermatol"},{"issue":"1","key":"4172_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/02841860310013702","volume":"43","author":"R Moore","year":"2004","unstructured":"Moore R, Doherty D, Chamberlain R, Khuri F (2004) Sex differences in survival in non-small cell lung cancer patients 1974\u20131998. Acta Oncol 43(1):57\u201364. https:\/\/doi.org\/10.1080\/02841860310013702","journal-title":"Acta Oncol"},{"issue":"6","key":"4172_CR11","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1016\/j.jaad.2019.12.068","volume":"87","author":"CA Nelson","year":"2022","unstructured":"Nelson CA, Singer S, Chen T, Puleo AE, Lian CG, Wei EX, Giobbie-Hurder A, Mostaghimi A, LeBoeuf NR (2022) Bullous pemphigoid after anti-programmed death-1 therapy: a retrospective case-control study evaluating impact on tumor response and survival outcomes. J Am Acad Dermatol 87(6):1400\u20131402. https:\/\/doi.org\/10.1016\/j.jaad.2019.12.068","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"4172_CR12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1805131","volume":"379","author":"MR Migden","year":"2018","unstructured":"Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, Rabinowits G, Thai AA, Dunn LA, Hughes BGM, Khushalani NI, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker HM, Brana I, Gil-Martin M, Homsi J, Johnson ML, Moreno V, Niu J, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG (2018) PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 379(4):341\u2013351. https:\/\/doi.org\/10.1056\/NEJMoa1805131","journal-title":"N Engl J Med"},{"issue":"4","key":"4172_CR13","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/labinvest.3780380","volume":"75","author":"T Yamada","year":"1996","unstructured":"Yamada T, Endo R, Tsukagoshi K, Fujita S, Honda K, Kinoshita M, Hasebe T, Hirohashi S (1996) Aberrant expression of a hemidesmosomal protein, bullous pemphigoid antigen 2, in human squamous cell carcinoma. Lab Invest 75(4):589\u2013600. https:\/\/doi.org\/10.1038\/labinvest.3780380","journal-title":"Lab Invest"},{"key":"4172_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1416473","volume":"15","author":"F Russo","year":"2024","unstructured":"Russo F, Pira A, Mariotti F, Papaccio F, Giampetruzzi AR, Bellei B, Di Zenzo G (2024) The possible and intriguing relationship between bullous pemphigoid and melanoma: speculations on significance and clinical relevance. Front Immunol 15:1416473. https:\/\/doi.org\/10.3389\/fimmu.2024.1416473","journal-title":"Front Immunol"},{"key":"4172_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.963401","volume":"13","author":"Y Mai","year":"2022","unstructured":"Mai Y, Izumi K, Mai S, Ujiie H (2022) The significance of preclinical anti-BP180 autoantibodies. Front Immunol 13:963401. https:\/\/doi.org\/10.3389\/fimmu.2022.963401","journal-title":"Front Immunol"},{"issue":"17","key":"4172_CR16","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3622","volume":"100","author":"Z Albadri","year":"2020","unstructured":"Albadri Z, Thorslund K, H\u00e4bel H, Seifert O, Gr\u00f6nhagen C (2020) Increased risk of squamous cell carcinoma of the skin and lymphoma among 5,739 patients with bullous pemphigoid: a Swedish nationwide cohort study. Acta Derm Venereol 100(17):adv00289. https:\/\/doi.org\/10.2340\/00015555-3622","journal-title":"Acta Derm Venereol"},{"issue":"22","key":"4172_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222212233","volume":"22","author":"J Tuusa","year":"2021","unstructured":"Tuusa J, Kokkonen N, Tasanen K (2021) BP180\/collagen XVII: a molecular view. Int J Mol Sci 22(22):12233. https:\/\/doi.org\/10.3390\/ijms222212233","journal-title":"Int J Mol Sci"},{"issue":"8","key":"4172_CR18","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1001\/jamadermatol.2022.1624","volume":"158","author":"MS Asdourian","year":"2022","unstructured":"Asdourian MS, Shah N, Jacoby TV, Reynolds KL, Chen ST (2022) Association of bullous pemphigoid with immune checkpoint inhibitor therapy in patients with cancer: a systematic review. JAMA Dermatol 158(8):933\u2013941","journal-title":"JAMA Dermatol"},{"key":"4172_CR19","doi-asserted-by":"publisher","DOI":"10.5070\/D327955136","author":"EM Klepper","year":"2021","unstructured":"Klepper EM, Robinson HN (2021) Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature. Dermatol Online J. https:\/\/doi.org\/10.5070\/D327955136","journal-title":"Dermatol Online J"},{"issue":"6","key":"4172_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15466","volume":"35","author":"MF Molle","year":"2022","unstructured":"Molle MF, Capurro N, Herzum A, Micalizzi C, Cozzani E, Parodi A (2022) Self-resolving bullous pemphigoid induced by cemiplimab. Dermatol Ther 35(6):e15466. https:\/\/doi.org\/10.1111\/dth.15466","journal-title":"Dermatol Ther"},{"issue":"1","key":"4172_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41572-025-00595-5","volume":"11","author":"H Akbarialiabad","year":"2025","unstructured":"Akbarialiabad H, Schmidt E, Patsatsi A, Lim YL, Mosam A, Tasanen K, Yamagami J, Daneshpazhooh M, De D, Cardones ARG, Joly P, Murrell DF (2025) Bullous pemphigoid. Nat Rev Dis Primers 11(1):16. https:\/\/doi.org\/10.1038\/s41572-025-00595-5","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"4172_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12924","volume":"32","author":"E Leavitt","year":"2019","unstructured":"Leavitt E, Holland V (2019) A case of atezolizumab-induced photodistributed bullous pemphigoid. Dermatol Ther 32(4):e12924. https:\/\/doi.org\/10.1111\/dth.12924","journal-title":"Dermatol Ther"},{"key":"4172_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1104360","volume":"14","author":"F Schauer","year":"2023","unstructured":"Schauer F, Tasiopoulou G, Schuster D, Behrens M, M\u00fcller S, Kiritsi D (2023) Primate liver tissue substrate in indirect immunofluorescence diagnostics for patients with dermatitis herpetiformis and celiac disease. Front Immunol 14:1104360. https:\/\/doi.org\/10.3389\/fimmu.2023.1104360","journal-title":"Front Immunol"},{"issue":"5","key":"4172_CR24","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.jaad.2020.01.049","volume":"83","author":"N van Beek","year":"2020","unstructured":"van Beek N, Kr\u00fcger S, Fuhrmann T, Lemcke S, Goletz S, Probst C, Komorowski L, Di Zenzo G, Dmochowski M, Drenovska K, Horn M, Jedlickova H, Kowalewski C, Medenica L, Murrell D, Patsatsi A, Geller S, Uzun S, Vassileva S, Zhu X, Fechner K, Zillikens D, St\u00f6cker W, Schmidt E, Rentzsch K (2020) Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technology. J Am Acad Dermatol 83(5):1315\u20131322. https:\/\/doi.org\/10.1016\/j.jaad.2020.01.049","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"4172_CR25","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1038\/jid.2011.180","volume":"131","author":"G Di Zenzo","year":"2011","unstructured":"Di Zenzo G, Thoma-Uszynski S, Calabresi V, Fontao L, Hofmann SC, Lacour JP, Sera F, Bruckner-Tuderman L, Zambruno G, Borradori L, Hertl M (2011) Demonstration of epitope-spreading phenomena in bullous pemphigoid: results of a prospective multicenter study. J Invest Dermatol 131(11):2271\u20132280. https:\/\/doi.org\/10.1038\/jid.2011.180","journal-title":"J Invest Dermatol"},{"issue":"7","key":"4172_CR26","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1111\/1346-8138.13809","volume":"44","author":"D Tie","year":"2017","unstructured":"Tie D, Yoshida T, Chinuki Y, Da X, Ishikawa N, Morita E (2017) Case of bullous pemphigoid coexisting with anti-desmoglein autoantibodies. J Dermatol 44(7):822\u2013825. https:\/\/doi.org\/10.1111\/1346-8138.13809","journal-title":"J Dermatol"},{"issue":"3","key":"4172_CR27","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1346-8138.2010.00801.x","volume":"37","author":"F Yamaki","year":"2010","unstructured":"Yamaki F, Mayuzumi N, Ikeda S, Hashimoto T (2010) Immunoglobulin A antibodies against desmoglein 1, envoplakin, periplakin and BP230 in a patient with atypical bullous pemphigoid. J Dermatol 37(3):255\u2013258. https:\/\/doi.org\/10.1111\/j.1346-8138.2010.00801.x","journal-title":"J Dermatol"},{"issue":"3","key":"4172_CR28","doi-asserted-by":"publisher","first-page":"e235","DOI":"10.1111\/ajd.12987","volume":"60","author":"X Grimaux","year":"2019","unstructured":"Grimaux X, Delva R, Jadaud E, Croue A (2019) Nivolumab-induced bullous pemphigoid after radiotherapy and abscopal effect. Australas J Dermatol 60(3):e235\u2013e236. https:\/\/doi.org\/10.1111\/ajd.12987","journal-title":"Australas J Dermatol"},{"key":"4172_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.731774","volume":"12","author":"X Zhang","year":"2021","unstructured":"Zhang X, Sui D, Wang D, Zhang L, Wang R (2021) Case report: A rare case of pembrolizumab-induced bullous pemphigoid. Front Immunol 12:731774. https:\/\/doi.org\/10.3389\/fimmu.2021.731774","journal-title":"Front Immunol"},{"issue":"6","key":"4172_CR30","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jamadermatol.2017.0091","volume":"153","author":"L Sowerby","year":"2017","unstructured":"Sowerby L, Dewan AK, Granter S, Gandhi L, LeBoeuf NR (2017) Rituximab treatment of nivolumab-induced bullous pemphigoid. JAMA Dermatol 153(6):603\u2013605. https:\/\/doi.org\/10.1001\/jamadermatol.2017.0091","journal-title":"JAMA Dermatol"},{"issue":"6","key":"4172_CR31","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.jaad.2022.01.016","volume":"86","author":"G Battesti","year":"2022","unstructured":"Battesti G, Garcia C, Viguier M, Marchal V, Castel M, Joly P, Ledard AP, Konstantinou MP, Seta V, Cordel N, Duvert-Lehembre S, Tancr\u00e8de-Bohin E, Belmondo T, Ingen-Housz-Oro S, d\u2019Incan M (2022) Real-life impact of immunologic tests to predict relapse after treatment cessation in patients with bullous pemphigoid: a French multicenter retrospective study. J Am Acad Dermatol 86(6):1293\u20131300","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"4172_CR32","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1111\/1346-8138.15816","volume":"48","author":"I Ujiie","year":"2021","unstructured":"Ujiie I, Iwata H, Yoshimoto N, Izumi K, Shimizu H, Ujiie H (2021) Clinical characteristics and outcomes of bullous pemphigoid patients with versus without oral prednisolone treatment. J Dermatol 48(4):502\u2013510. https:\/\/doi.org\/10.1111\/1346-8138.15816","journal-title":"J Dermatol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04172-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04172-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04172-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:45:25Z","timestamp":1764600325000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04172-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":32,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4172"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04172-3","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"6 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was reviewed and approved by the institutional Helsinki Committee (Approval No. 0483-22-RMB) in accordance with the Declaration of Helsinki. Written informed consent was waived as the study was conducted using anonymized sera, as approved by the ethics committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"360"}}